IGC Pharma announces patient enrollment at Neurostudies in Phase 2 trial investigating IGC-AD1
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
The collaboration aims to bolster healthcare entrepreneurship
The award recognizes powerful science–industry collaborations for social good
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Subscribe To Our Newsletter & Stay Updated